Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

Saturday, April 25, 2009

Trimethylaminuria research proposal by Dr John Christodoulou

Unfortunately funding has not been found for this proposal.

An intro by Rob for this post will follow later:

Below is a full copy of the proposed trimethylaminuria research to (hopefully) be conducted by Dr John Christodoulou et al in Australia

It can also be found hosted here : Australian TMAU research proposal : full paper

Study component
Year 1
Year 2
Year 3
Development of urinary quantitation of TMA & TMAO
Development of molecular screening of FMO3 gene
Generation of the mouse model for FMO3 deficiency, & biochemical and phenotypic characterisation
Generation of a range of FMO3 nonsense mutations, & their functional analysis in a cell culture system
Evaluation of the efficacy of PTC124 in our in vitro cell culture system
Evaluation of the efficacy of PTC124 in our mouse model system
Evaluation of the therapeutic utility of Methylophilus methylotrophus in our mouse model system

Research Proposal
Development of Diagnostic and Therapeutic Approaches to Trimethylaminuria
John Christodoulou1
Patrick Tam2
Kevin Carpenter1
March 2009

1 Western Sydney Genetics Program, The Children's Hospital at Westmead, Sydney, Disciplines of Paediatrics and Child Health & Genetic Medicine, University of Sydney, Sydney, New South Wales 2006, Australia.

2 Children’s Medical Research Institute, University of Sydney, Westmead, New South Wales 2145, Australia.

Address for Correspondence: Professor John Christodoulou, Western Sydney Genetics Program, Children's Hospital at Westmead, Locked Bag 4001, Westmead, New South Wales 2145, Australia.
Tel.: 612-9845 3452
Fax: 612-9845 1864

Clinical and laboratory diagnosis of trimethylaminuria:
The consequences of trimethylaminuria (TMAU) were recognized by Shakespeare (The Tempest, Act 2. Scene 2), and as elegantly stated in Trinculo’s monologue, once the diagnosis has been made it is like a bolt from the blue for affected individuals and their families.

Excess dietary choline is metabolised by anaerobic micro-organisms in the large intestine to trimethylamine, which in turn is converted to odourless trimethylamine N-oxide by the last step in the choline degradative pathway, flavin mono-oxygenase 3 (FMO3)1. Primary or secondary accumulation of trimethylamine has no deleterious physical effect, but can cause devastating social debilitation, because trimethylamine when eliminated in urine, sweat or breath, saliva and other body fluids has a very distinctive odour of decaying fish. The odour becomes more prominent during periods of stress, with fever and with strenuous exercise as a consequence of increased sweating1. In addition, dietary intake of marine fish exacerbates symptoms since these animals contain large amounts of trimethylamine-N-oxide (which is believed to have antifreeze properties), which can be converted back to trimethylamine by gut bacteria2.

Primary TMAU is most often caused by a functional defect of FMO33, and the genetic disorder is inherited in an autosomal recessive manner as a consequence of mutations in the FMO3 gene. At least 30 different mutations have been reported within the 9 coding exons of the FMO3 gene, which is located on the short arm of chromosome 14-6, and of those about a quarter are nonsense mutations7, although the proportion of patients with nonsense mutations is unknown. The incidence of TMAU due to FMO3 deficiency is not precisely known, but it has been suggested that it may range between 1 in 100 and 1 in 10005. What is certain is many people remain undiagnosed for unacceptably long periods of time8.

Secondary TMAU has been described in patients with severe liver disease (which is the major site of activity of the FMO3 enzyme)9, chronic renal disease (as a consequence of bacterial overgrowth in the gut)10, and in patients treated with large doses of betaine for disorders of cobalamin or homocysteine metabolism or possibly L-carnitine for organic acidopathies and fatty acid oxidation disorders1. In addition, transient TMAU has been reported in a preterm infant who was fed with choline-rich food supplements, such as egg yolk. Soy and liver11, and has been reported in some women just at the onset of menstruation9.

The key to establishing the diagnosis is suspecting it in the first place. TMAU sufferers have endured their disorder for years or even decades, often subject to ridicule by their peers and doubted by their health care professions, before the diagnosis has finally been established. Quantitation of trimethylamine and timethylamine-N-oxide in a random urine sample will confirm clinical suspicions, however it should be remembered that excessive trimethylamine excretion may be intermittent, so a normal single result does not rule out the disorder9. The diagnosis can be more firmly established by conducting a choline or marine fish load test1, or by FMO3 mutational analysis. Currently, there is only one laboratory in Australia offering biochemical testing for trimethylaminuria, but we believe this is suboptimal because this laboratory does not routinely quantitate trimethylamine-N-oxidase, potentially missing cases of the disorder. Best practice guidelines suggest that both trimethylamine and trimethylamine-N-oxidase should be measured1. Similarly, mutation screening of the FMO3 gene is not routinely available in Australia.

We propose to develop a comprehensive national service for the accurate biochemical and molecular screening for trimethylaminuria.

Current approaches to the management of trimethylaminuria:
The optimum management of TMAU usually needs to include a combination of approaches1, 9, 12 including:
  • dietary restriction of choline-containing foods (including egg yolk, liver and other organ meats, legumes, and products containing lecithin [322] and choline [1001], which are put into processed foods as emulsifiers) and marine fish (including cephalopods like octopus and squid and crustaceans like lobster, crab, prawns and balmain bugs)
  • low pH (5.5 – 6.5) soaps (eg goat’s milk soap), deodorants and body lotions (eg Lactcyd™)
  • copper-chlorophyll or activated charcoal, which are not absorbed across the gut, and which can irreversibly bind to trimethylamine in the gut thereby limiting its systemic absorption
  • probiotics to change the balance of gut flora
  • intermittent oral antibiotics to reduce the gut bacterial load

These treatments, however, are not perfect, and can be difficult to maintain consistently. No new approaches to the treatment of trimethylaminuria have been developed in recent decades. An important component of the development of new therapies is to have appropriate cell biological and animal models of the disorder, so that efficacy and safety of proposed new treatments can be tested.

New strategies for the treatment of trimethylaminuria:
Read through of premature termination mutations:
Premature termination or nonsense mutations arise as a result of a single nucleotide change in a gene where the change leads to the conversion of an amino acid in the protein sequence to a premature stop codon. Such mutations often result in the protein losing most if not all of its functional capacity. It was recognised a number of years ago that aminoglycoside antibiotics can force the transcriptional machinery to read through the premature stop mutations, and allow the normal protein to be made, restoring activity of the protein13. However, aminoglycoside antibiotics have significant side effects and are not a viable therapeutic option. More recently a new class of drugs has been developed that has the capacity to promote read through of premature termination mutations, and which appear to be totally non-toxic (Welch ref). One in particular, PTC124, has been shown to result in the production of normal dystrophin in the mdx mouse model of Duchenne muscular dystrophy14, and has been used in clinical trials in human subjects with cystic fibrosis, with clear benefits being found15. An inborn error of metabolism like TMAU would be an excellent candidate for this type of therapy, as an increase of enzyme activity to perhaps as little as 10% of normal should be enough to overcome the biochemical block.

We propose to use an in vitro (cell culture model) approach to determine whether PTC124 is of potential therapeutic value in this proportion of TMAU patients. If we demonstrate potential in vitro efficacy, we will then go on to study the efficacy of PTC124 in the mouse model.. This mouse model will have a premature termination mutation of FMO3 deficiency for testing of new therapies for trimethylaminuria.

Other strategies for metabolising TMA in the small intestine:
Anaerobic gut bacteria can contribute to the trimethylamine load in patients with TMAU by enhancing the metabolism of choline in food to trimethylamine in the gut1. As stated above, one form of therapy of TMAU, albeit in more extreme cases, is to treat patients with antibiotics aiming to reduce the intestinal load of these bacteria. However, the antibiotics that need to be used have potentially serious side effects, and so can only be used for short periods of time.

An alternative strategy for reducing the gut trimethylamine load would be to colonise the gut with harmless bacteria that are capable of metabolising trimethylamine. One such micro-organism is Methylophilus methylotrophus. This is an aerobic monoflagellate bacterium that uses methanol as the sole source of carbon and energy16. It was initially thought to be of potential commercial value in the single-cell protein production industry, but it proved to be a nonfinancial venture. When cultured in trimethylamine, the enzyme trimethylamine dehydrogenase is induced, which converts trimethylamine to dimethylamine and formaldehyde17. Extensive studies have shown that this micro-organism is non-pathogenic and non-toxic in animals18, 19. Therefore colonisation of the gut with Methylophilus methylotrophus in individuals with TMAU could be of potential therapeutic utility.

We propose to study the potential therapeutic benefit of Methylophilus methylotrophus in our mouse model of TMAU.

Research Plan:
  1. To develop comprehensive biochemical screening for trimethylaminuria
Previous methods have used an HPLC approach to quantitated trimethylamine in urine samples. This is a labour intensive method that has the added disadvantage that it does not easily lend itself to the quantitation of trimethylamine-N-oxide as well. We plan to use a mass spectrophotometric approach similar to that described by Johnson20. Co-chief investigator, Kevin Carpenter, head of the NSW Biochemical Genetics Service based at the Children’s Hospital at Westmead, is an international authority on the use of mass spectrometric techniques in the diagnosis of inborn errors of metabolism. He will oversee the development of the new more complete biochemical testing for TMAU. We have urine samples from patients with TMAU already in storage, and these will be used as positive controls for the development phase. This new testing procedure, coupled with a marine fish or choline load as needed1, will provide a very powerful means for diagnosis of the majority of TMAU patients.

  1. To develop complete molecular genetic screening of the FMO3 gene for individuals suspected of having trimethylaminuria.
John Christodoulou has nearly two decades of experience in the analysis of gene mutations, and his research laboratory has all of the facilities to be able to develop comprehensive mutation testing of the FMO3 gene. Once this testing has been developed to a robust stage, the methodology will be transferred to the molecular genetics diagnostic laboratory at the Children’s Hospital at Westmead, for which he is the administrative head, and so will be available as a routine diagnostic test on referral by clinicians in Australasia.

  1. To develop an in vitro system for testing whether PTC124 can correct the functional consequences of premature termination mutations of the FMO3 gene.
Using standard cloning techniques that are well established in our laboratories, we will generate a human FMO3 expression vector, and then use site-directed mutagenesis to generate all of the reported FMO3 nonsense mutations. We will then express them in a mammalian cell system (such as COS or HEK293 cells). We will develop a functional assay of the FMO3 enzyme, using previously reported spectrophotometric methods21, and then confirm that the mutations cause non- or dysfunctional FMO3 enzyme. CI Christodoulou and Carpenter have extensive experience in the use of spectrophotometric enzyme assays, have the necessary equipment to be able to establish this specific assay, and do not anticipate any major hurdles in establishing this method.

We will also perform western analysis of the wildtype and mutant proteins using commercially available antibodies (both Abcam and Abnova have an antibody against the human FMO3 protein which has been successfully used for western analyses) to identify those mutations which result in a stable but truncated protein and those mutations which result in the production of an unstable protein. Western analysis is a standard technique, and is very well established in the Christodoulou and Tam laboratories.

Having done these initial functional studies, we will then expose cells to varying concentrations of PTC124, and assay for improvement in functional activity, and perform westerns to determine whether full length protein is now being made. Initial discussions with senior staff from Genzyme Therapeutics, the current patent holder of PTC124, suggest that we will be able to obtain as supply of the drug for our studies.

  1. To develop a mouse model with a premature termination mutation of FMO3 deficiency, and to study the biochemical and phenotypic consequence of this mutation in the mouse.
The outcome of the cell culture study in Aim 3 will inform us of the most specific nonsense mutation that will cause a premature termination of transcription and can respond to the read-through activity mediated by PTC124 to restore the normal protein function. We will create a similar mutation in the mouse genome by inserting the specific single-nucleotide change into the Fmo3 gene. This will be achieved by gene targeting techniques on mouse embryonic stem cells. The engineered cells will be used to generate live mice that carry the specific mutation. The genetically modified mice will be assessed for the levels of trimethylamine and trimethylamine-N-oxide, using the mass spectrometric techniques developed for Plan 1, to ascertain that they display the clinical features of trimethylaminuria.

  1. To test the in vivo efficacy of PTC124 in our mouse model of FMO3 deficiency.
Having developed a mouse model with a nonsense mutation of the Fmo3 gene and demonstrating that recapitulates the human TMAU disorder, we will be in an excellent position to explore the in vivo efficacy of PTC124.

We will quantitate trimethylamine and trimethylamine-N-oxide levels in urine samples from wildtype and mutant mice fed on normal chow, and if necessary a chow rich in choline. We will also careful monitor the health and behaviour of the mice, although we do not expect to find any physical or behavioural abnormalities in the mutant mice. The mice will then be euthanised, livers harvested, and we will go on to then evaluate FMO3 enzyme activity in the livers of wildtype and mutant mice, the organ which primarily expresses FMO322, and quantitate FMO3 the level of and the size of the wildtype and mutant FMO3 protein extracted from liver samples.

We will then inject PTC124 intraperitoneally into wildtype and mutant mice at varying doses and time intervals. During this time we will monitor the health of the mice, and collect urine samples for quantitation of trimethylamine and trimethylamine-N-oxide. We will then euthanise the mice, collect their livers, and assay for FMO3 activity and examine the FMO3 protein by western to test whether mutant mice are now able to generate a full length functional FMO3 protein.

  1. To test the therapeutic efficacy of Methylophilus methylotrophus as a therapeutic adjunct in our mouse model of FMO3 deficiency.
An aliquot of the Methylophilus methylotrophus micro-organism will be sourced and culture stocks will be established. We will apply the same methodology as in aim 5 to examine the potential therapeutic effects of intragastrically delivered Methylophilus methylotrophus, again given at varying doses and intervals.

As a result of the research program outlined in this proposal we will have established a comprehensive national diagnostic service for TMAU. In addition, we will have developed the unique resource of a mouse model for TMAU, which will be of great value in assessing new therapeutic approaches to the disorder. We will also have demonstrated whether PTC124 is able to correct functional defects of FMO3 for subset of mutations, and will have shown whether it is also of in vivo efficacy in our mouse model. Finally, we will have examined whether the micro-organism Methylophilus methylotrophus is of potential therapeutic value in our mouse model for TMAU. We believe that these outcomes will represent a major advance on the current state of play with regards to the diagnosis and treatment of patients with TMAU in Australia.

Time-lines for the project (at half-yearly milestones):

Study component
Year 1
Year 2
Year 3
Development of urinary quantitation of TMA & TMAO
Development of molecular screening of FMO3 gene
Generation of the mouse model for FMO3 deficiency, & biochemical and phenotypic characterisation
Generation of a range of FMO3 nonsense mutations, & their functional analysis in a cell culture system
Evaluation of the efficacy of PTC124 in our in vitro cell culture system
Evaluation of the efficacy of PTC124 in our mouse model system
Evaluation of the therapeutic utility of Methylophilus methylotrophus in our mouse model system

1 Chalmers RA, Bain MD, Michelakakis H, Zschocke J, Iles RA. Diagnosis and management of trimethylaminuria (FMO3 deficiency) in children. J Inher Metab Dis 2006; 29: 162-172
2 Arseculeratne G, Wong AK, Goudie DR, Ferguson J. Trimethylaminuria (fish-odor syndrome): a case report. Arch Dermatol 2007; 143: 81-84
3 Ayesh R, Mitchell SC, Zhang A, Smith RL. The fish odour syndrome: biochemical, familial and clinical aspects. Br Med J 1993; 307: 655-657
4 Hernandez D, Addou S, Lee D, Orengo C, Shephard EA, Phillips IR. Trimethylaminuria and a human FMO3 mutation database. Human Mut 2003; 22: 209-213
5 Cashman JR. The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and development. Drug Discov Today 2004; 9: 574-581
6 Yamazaki H, Fujita H, Gunji T, Zhang J, Kamataki T, Cashman JR, Shimizu M. Stop codon mutations in the flavin-containing monooxygenase 3 (FMO3) gene responsible for trimethylaminuria in a Japanese population. Molec Genet Metab 2007; 90: 58-63
7 Phillips IR, Shephard EA. Flavin-containing monooxygenases: mutations, disease and drug response. Trends Pharmacol Sci 2008; 29: 294-301
8 Mountain H, Brisbane JM, Hooper AJ, Burnett JR, Goldblatt J. Trimethylaminuria (fish malodour syndrome): a "benign" genetic condition with major psychosocial sequelae. Med J Aust 2008; 189: 468
9 Mitchell SC, Smith RL. Trimethylaminuria: the fish malodor syndrome. Drug Metab Dispos 2001; 29: 517-521
10 Rehman HU. Fish odor syndrome. Postgrad Med J 1999; 75: 451-452
11 Blumenthal I, Lealman GT, Franklyn PP. Fracture of the femur, fish odour and copper deficiency in a preterm infant. Arch Dis Child 1980; 55: 229-231
12 Busby MG, Fischer L, da Costa KA, Thompson D, Mar MH, Zeisel SH. Choline- and betaine-defined diets for use in clinical research and for the management of trimethylaminuria. J Amer Diet Assoc 2004; 104: 1836-1845
13 Hermann T. Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell Mol Life Sci 2007; 64: 1841-1852
14 Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447: 87-91
15 Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J, Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B, Wilschanski M. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372: 719-727
16 Dawson MJ, Jones CW. Respiration-linked proton translocation in the obligate methylotrpph Methylophilus methylotrophus. Biochem J 1981; 194: 915-924
17 Shi W, Mersfelder J, Hille R. The interaction of trimethylamine dehydrogenase and electron-transferring flavoprotein. J Biol Chem 2005; 280: 20239-20246
18 Hambleton P, Melling J, Salusbury TT. Biosafety in Industrial Biotechnology. London: Springer, 1994
19 Stringer DA. Industrial development and evaluation of new protein sources: micro-organisms. Proc Nutr Soc 1982; 41: 289-300
20 Johnson DW. A flow injection electrospray ionization tandem mass spectrometric method for the simultaneous measurement of trimethylamine and trimethylamine N-oxide in urine. J Mass Spectrom 2008; 43: 495-499
21 Zhang J, Cerny MA, Lawson M, Mosadeghi R, Cashman JR. Functional activity of the mouse flavin-containing monooxygenase forms 1, 3, and 5. J Biochem Mol Toxicol 2007; 21: 206-215
22 Krueger SK, Williams DE. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 2005; 106: 357-387

Proposed Budget:
Given to wide range of techniques, their complexity and the volume of work that will need to be undertaken, funding for two postdoctoral research scientists is required. It is expected that these individuals will have at least five years postdoctoral research experience, and will be adept in general molecular and cloning techniques, mouse experimental work, bacterial and mammalian cell culture work, and the various biochemical and protein based studies that will need to be undertaken.

Each scientist will be employed at Research Officer HSM1 level:
Annual salary (including base salary, and all on costs) $88,573

[$177,146 per year]

Molecular Biological Reagents:
dNTPs, Taq polymerase, restriction enzymes, ligases, kinases, agarose, "clean-up" kits, antibodies for westerns, plasmid miniprep kits, MW markers, oligos for sequencing and PCR [$12,000 per yr]

General Cell Culture Reagents:
Plasticware and tissue culture reagents: for culturing mammalian cell lines and their manipulation, including DMEM/F12 media, PBS, FBS, etc. [$7,500 per year]

General Laboratory Reagents:
Buffers, solvents, salts, acrylamide, microfuge tubes, pipette tips, foil, cleaning supplies, gloves, syringes, parafilm, reagents for FMO3 enzyme assays, etc. [$5,500 per yr]

Mouse Agistment Costs:
1 large box (houses 10 mice) = $8.00/week
1 small box (houses mating pair or pregnant mice) = $5.50/week
15 small boxes (to house neonatal, juvenile and adult mice) for 20 weeks - 15 x $5.50/week x 15 = $1650
6 large boxes (to house female mice in preparation for breeding) for 52 weeks - 4 x $8.00 x 52 = $2496
10 small boxes (to house a breeding pair then the pregnant mouse) for 52 weeks - 10 x $5.50 x 52 = $2860
Total holding cost $7006
Animal health monitoring costs $2214/yr
[Total Animal Cost = holding + health monitoring = $ 9220/yr]
Mouse experimental work will take place over 3.0 yr (total cost = $27660).

Annual budget requested: $211,266

Total budget requested for the life of this 3-year research proposal: $633,798


Anonymous said...

Brilliant news

Mar 18, 2015, 2:29:00 PM
Post a Comment